Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer
Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Alternating pazopanib and bevacizumab found superior to pazopanib alone
- Strategy aims to delay onset of resistance to pazopanib
- Study reveals median progression-free survival of 23.3 months
- Alternating pazopanib and bevacizumab found superior to pazopanib alone
- Strategy aims to delay onset of resistance to pazopanib
- Study reveals median progression-free survival of 23.3 months
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link